Healio

FDA grants orphan drug designation for ATSN-201 for X-linked retinoschisis

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. ATSN-201 received orphan drug designation from the FDA ...
Healio

FDA grants fast track designation to X-linked retinoschisis treatment

Please provide your email address to receive an email when new articles are posted on . ATSN-201 is being evaluated for the treatment of X-linked retinoschisis. The gene therapy previously received ...
Seeking Alpha

Atsena Therapeutics Announces Positive Clinical Data from Part A of Phase I/II Trial Evaluating ATSN-201 Gene Therapy to Treat X-linked Retinoschisis (XLRS)

Majority of patients demonstrated successful efficacy readouts across structural measurements (foveal schisis closure) and had meaningful improvement on visual function measurements including MP, BCVA ...
MarketWatch

Atsena Completes Dosing in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-linked Retinoschisis and Announces Plans for Initiation of Pivotal Part ...

DURHAM, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, ...